NCT04006054 is a Phase 4 clinical trial of Dexmedetomidine in Traumatic Brain Injury, sponsored by Xiangya Hospital of Central South University.

Who is sponsoring NCT04006054?

NCT04006054 is sponsored by Xiangya Hospital of Central South University.

What drugs are being tested in NCT04006054?

Interventions in NCT04006054: Dexmedetomidine, Midazolam.

What condition does NCT04006054 study?

NCT04006054 studies Traumatic Brain Injury.

Is NCT04006054 still recruiting?

NCT04006054 is currently status unknown. Last updated 2 July 2019.

Last reviewed 2019-07-02 · How we verify

NCT04006054

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on Cerebral Protection of Dexmedetomidine for Patients With Traumatic Brain Injury

Status unknown Phase 4 Last updated 2 July 2019

What this trial tests

Phase 4 trial testing Dexmedetomidine in Traumatic Brain Injury in 82 participants. Status unknown.

Timeline

6 June 2019

Primary endpoint
30 June 2021

30 December 2021

Quick facts

Lead sponsor	Xiangya Hospital of Central South University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	82
Start date	6 June 2019
Primary completion	30 June 2021
Estimated completion	30 December 2021
Sites	1 location across China

Drugs / interventions tested

Dexmedetomidine (dexmedetomidine) — full drug profile →
Midazolam (midazolam) — full drug profile →

Conditions studied

Traumatic Brain Injury — all drugs for Traumatic Brain Injury →

Sponsor

Xiangya Hospital of Central South University

Who can join

Adults 18 to 70, any sex, with Traumatic Brain Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to investigate whether dexmedetomidine could suppress catecholamine release into peripheral blood to prevent PSH attacks and to achieve neuroprotection.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current Clinical Trials in Traumatic Brain Injury.
Ahmed Z. · · 2022 · cited 23× · PMID 35624914 · DOI 10.3390/brainsci12050527
Traumatic brain injury and immunological outcomes: the double-edged killer.
Datta S, Lin F, Jones LD, Pingle SC, et al · · 2023 · cited 10× · PMID 37228857 · DOI 10.2144/fsoa-2023-0037

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
NCT07398066 — DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial) · NA · not yet recruiting
NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07306702 — Dexmedetomidine-Enhanced PCIA After Lobectomy in Nicotine-Dependent Patients · Phase 4 · withdrawn
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting

Other recruiting trials for Traumatic Brain Injury

Currently open trials in the same condition.

NCT07176936 — Improving Speech in Noise Using Noninvasive Stimulation · NA · recruiting
NCT07473505 — Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospect · recruiting
NCT07455136 — A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Mon · recruiting
NCT07404761 — Safety and Effectiveness of Spatial StimelMD (SSMD) in Subjects With Upper Limb Neuromotor Impairments · NA · recruiting
NCT07230002 — Effects of Moderate/Severe Traumatic Brain Injury in the Subacute or Chronic Phase on Locomotor Strategies Involved in N · NA · recruiting

Other Xiangya Hospital of Central South University trials

Trials by the same sponsor.

NCT07482670 — Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases · not yet recruiting
NCT07412223 — Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery · Phase 4 · not yet recruiting
NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
NCT07369999 — Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke · Phase 3 · not yet recruiting
NCT07309913 — China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04006054 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiangya Hospital of Central South University
Last refreshed: 2 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04006054.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing